Breaking News Instant updates and real-time market news.

RARX

RA Pharmaceuticals

$16.45

0.25 (1.54%)

07:11
12/10/18
12/10
07:11
12/10/18
07:11

RA Pharmaceuticals to host conference call

Conference call to discuss positive top-line results from Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis will be held on December 10 at 8 am. Webcast Link

  • 10

    Dec

  • 12

    Dec

RARX RA Pharmaceuticals
$16.45

0.25 (1.54%)

10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
10/10/18
RAJA
10/10/18
UPGRADE
RAJA
Strong Buy
RA Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
08/08/18
RAJA
08/08/18
NO CHANGE
Target $28
RAJA
Outperform
RA Pharmaceuticals price target raised to $28 from $18 at Raymond James
07/20/18
BMOC
07/20/18
INITIATION
Target $20
BMOC
Outperform
RA Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini initiated RA Pharmaceuticals with an Outperform rating and $20 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.